Old North State Trust LLC Sells 683 Shares of Johnson & Johnson (NYSE:JNJ)

Old North State Trust LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,515 shares of the company’s stock after selling 683 shares during the period. Johnson & Johnson accounts for approximately 1.2% of Old North State Trust LLC’s investment portfolio, making the stock its 17th biggest holding. Old North State Trust LLC’s holdings in Johnson & Johnson were worth $1,748,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $25,000. Krane Funds Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $26,000. Crewe Advisors LLC boosted its holdings in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. boosted its holdings in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Thor Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at $69,000. Institutional investors own 72.01% of the company’s stock.

Shares of NYSE JNJ traded down $2.62 during mid-day trading on Wednesday, hitting $129.22. 7,851,413 shares of the stock traded hands, compared to its average volume of 7,081,184. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The company has a market cap of $352.75 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 2.26 and a beta of 0.69. The firm has a 50 day simple moving average of $130.02 and a two-hundred day simple moving average of $135.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter last year, the business posted $2.10 EPS. Johnson & Johnson’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

A number of equities research analysts have weighed in on JNJ shares. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a report on Thursday, July 18th. Raymond James reduced their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Finally, Bank of America reaffirmed a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What are municipal bonds?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.